ClinicalTrials.gg
CompletedNCT04388904ReSTARTUpdated Apr 26, 2024

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

A Phase 4 interventional study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC) in HIV-1-infection, sponsored by The Crofoot Research Center, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-26.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by The Crofoot Research Center, Inc. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to demonstrate the effectiveness of Symtuza® in a rapid reinitiation model of care in patients with HIV-1 infection and who are treatment-experienced but have been off of antiretroviral therapy (ART) for 12 or more weeks.

Read the detailed description

In the United States, only 49 percent of persons living with HIV infection are currently retained in care (Centers for Disease Control, 2018). Many individuals initially start antiretroviral therapy (ART) but fall out of care and discontinue treatment, only to reenter care at a later date. Gaps in care contribute to the likelihood that a patient might not have a recent viral load or CD4 count, as well as knowledge of previous ART regimens or resistance data. Furthermore, high plasma HIV-1 RNA is a major risk factor for HIV transmission, and effective ART can reduce viremia and transmission of HIV to sexual partners by more than 96% (Cohen et al., 2011; Palella et al., 1998). Thus, a secondary goal of ART is to reduce the risk of HIV transmission.

Traditional models of care have an initial period where a person is brought back into care and assessed by a healthcare provider on various factors, including HIV RNA level, genotypic/ phenotypic resistance, immune status, renal/hepatic function, and general medical comorbidities before reinitiating ART. These steps can add weeks without treatment and, in turn, delay resupression of the virus and immune system improvement, as well as continuing to contribute to the community viral load and offering more opportunities for the person to fall out of care again. (Horburg et al., 2013) This traditional model places a burden on both the patient and the healthcare system as multiple visits are required, each one a potential point where the patient can be lost again to follow-up.

A rapid reinitiation of ART for persons who have fallen out of care is a potential intervention that could improve retention rates, patient satisfaction, and clinical outcomes. Given these factors, the single-tablet regimen of D/C/F/TAF (Symtuza®) may serve as an ideal regimen for a Rapid Reinitiation model of care, combining potency, sustained efficacy, a high genetic barrier to resistance, with a well-described safety profile of the individual components, and practical, convenient dosing.

This prospective, multicenter study will follow subjects for 48 weeks with subjects either returning to the site or having a virtual visit (TeleVisit) for Weeks 2, 4, 12, 24, 36, and 48. Baseline safety labs will dictate whether the ART regimen will need to be modified but will not be required to be completed at the initiation of ART. Assessment of drug accountability, reasons for non-adherence, recording of concomitant therapies, adverse events, weight, physical examinations (complete or symptom-directed), laboratory evaluations (for efficacy and safety), and health outcome assessments will be performed from baseline onwards.

02

Conditions studied

  • HIV-1-infection

Keywords

  • Acquired Immunodeficiency Syndrome
  • HIV Infections
  • Sexually Transmitted Diseases, Viral
  • Anti-Retroviral Agents
  • Antiviral Agents
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 75 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

This is the only study on the registry with The Crofoot Research Center, Inc. as lead sponsor.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age at screening/baseline visit.
  • Antiretroviral treatment-experienced and have not received any anti- treatment within 12 weeks prior to screening.
  • use by men or women should be consistent with the local regulations regarding the use of contraceptive methods for subject participating in clinical studies.
  • Men must agree not to donate sperm during the study until 90 days after receiving the last dose of study drug (or longer, if dictated by local regulations).
  • Must be able to swallow whole tablets or swallow tablets cut into halves.

Exclusion criteria

Exclusion Criteria:

  • Known active cryptococcal infection, active toxoplasmic encephalitis, Mycobacterium tuberculosis infection, or another AIDS-defining condition that in the judgment of the investigator would increase the risk of morbidity or mortality.
  • Known resistance to any of the components of D/C/F/TAF; subjects with known or identified FTC resistance attributed to an M184V mutation alone will be permitted to remain in the study.
  • Prior virologic failure on a DRV-containing regimen from known history or from medical records.
  • Known history of hepatic disease or hepatitis that in the investigator's judgment is not compatible with D/C/F/TAF.
  • Known history of severe hepatic impairment as diagnosed based on documented history of severe hepatic impairment ( C).
  • Known history of chronic (≥3 months) renal insufficiency, defined as having an \<30 mL/min according to the MDRD formula.
  • Pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 90 days after the last dose of study treatment.
  • Plans to father a child while enrolled in this study or within 90 days after the last dose of study treatment.
  • Current alcohol or substance use judged by the investigator to potentially interfere with subject study adherence.
  • Known history of within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma.
  • Known active, severe infections (other than -1 infection) requiring parenteral antibiotic or antifungal therapy that in the judgment of the investigator would increase the risk of morbidity or mortality.
  • Any other condition or prior therapy for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the wellbeing) or that could prevent, limit, or confound the protocol-specified assessments.
  • Subject unlikely to comply with the protocol requirements based on clinical judgment.
  • Received an drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the planned first dose of study treatment or is currently enrolled in an investigational study.
  • Subjects receiving ongoing therapy with , not recommended, drugs that cannot be adequately dose-adjusted, or subjects with any known allergies to the of the D/C/F/TAF.
  • Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator, or employees of Johnson \& Johnson.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)

    Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.

    Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)

Interventions

  • DrugDarunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)

    Drug pages: Darunavir · Cobicistat · Emtricitabine · Tenofovir alafenamide

    Participants will receive Symtuza®. An oral tablet containing Darunavir 800 mg /Cobicistat 150 mg /Emtricitabine 200 mg /Tenofovir Alafenamide 10 mg FDC, once daily within 24 hours of the screening/ baseline visit.

06

What researchers measure

Primary outcomes

  1. The proportion of subjects who have HIV-1 RNA <50 copies/mL at week 48

    The proportion of subjects who have HIV-1 RNA \<50 copies/mL at week 48 as defined by the FDA snapshot analysis (ITT)

    Time frame: 48 week

Secondary outcomes

  1. Proportion of subjects who have HIV-1 RNA <50 copies/mL at week 48

    Proportion of subjects who have HIV-1 RNA \<200 copies/mL at week 48 as defined by the per-protocol (PP) analysis set

    Time frame: Week 48

  2. Proportion of subjects who have HIV-1 RNA <50 copies/mL at week 48

    Proportion of subjects who have HIV-1 RNA \<200 copies/mL at week 48 as defined by the FDA snapshot analysis (ITT)

    Time frame: Week 48

  3. Proportion of subjects who have HIV-1 RNA <200 copies/mL at week 24

    Proportion of subjects who have HIV-1 RNA \<200 copies/mL at week 24 as defined by the FDA snapshot analysis (ITT)

    Time frame: Week 24

  4. Change from baseline in HIV-1 RNA viral load

    Change from baseline in log10 HIV-1 RNA viral load at Weeks 24 and 48

    Time frame: Weeks 24 and 48

  5. Change in baseline CD4 cell count

    Change in baseline CD4 cell count at Weeks 12, 24, and 48

    Time frame: Weeks 12, 24, and 48

  6. Discontinuation after enrollment based on study stopping rules

    Proportion of subjects that required discontinuation after enrollment based on study stopping rules

    Time frame: Week 48

  7. Discontinuation due to adverse events

    Proportion of subjects discontinuing therapy due to adverse events

    Time frame: Week 48

  8. Proportion of subjects experiencing grade 3 and 4 adverse events

    Proportion of subjects experiencing grade 3 and 4 adverse events

    Time frame: Week 48

  9. Proportion of subjects experiencing serious adverse events

    Proportion of subjects experiencing serious adverse events

    Time frame: Week 48

  10. Proportion of subjects experiencing grade 3 and 4 laboratory abnormalities

    Proportion of subjects experiencing grade 3 and 4 laboratory abnormalities

    Time frame: Week 48

  11. Proportion of subjects meeting resistance stopping rules requiring discontinuation of study drugs due baseline resistance findings

    Proportion of subjects meeting resistance stopping rules requiring discontinuation of study drugs due baseline resistance findings

    Time frame: Week 48

  12. Proportion of subjects with baseline RT, INI, and PR (primary and secondary) RAMs

    Proportion of subjects with baseline RT, INI, and PR (primary and secondary) RAMs

    Time frame: Week 48

  13. Proportion of subjects developing RAMs and loss of phenotypic susceptibility, when available, upon meeting PDVF

    Proportion of subjects developing RAMs and loss of phenotypic susceptibility, when available, upon meeting PDVF

    Time frame: Week 48

  14. Proportion of subjects with PDVF at Week 24 and Week 48

    Proportion of subjects with PDVF at Week 24 and Week 48

    Time frame: Weeks 24 and 48

  15. Proportion of subjects lost to follow-up throughout the 48 Weeks of treatment

    Proportion of subjects lost to follow-up throughout the 48 Weeks of treatment

    Time frame: Week 48

  16. Proportion of subjects taking study drug at Week 48 who have a documented clinic visit with a healthcare provider within 90 days of Week 48 visit.

    Proportion of subjects taking study drug at Week 48 who have a documented clinic visit with a healthcare provider within 90 days of Week 48 visit.

    Time frame: Week 48

  17. Mean total satisfaction scores on the HIVTSQs at Weeks 4, 24, and 48

    Mean total satisfaction scores on the HIVTSQs at Weeks 4, 24, and 48

    Time frame: Weeks 4, 24, and 48

  18. Mean total depression scores on the PHQ-9 at baseline and Weeks 4, 24, and 48

    Mean total depression scores on the PHQ-9 at baseline and Weeks 4, 24, and 48

    Time frame: Weeks 4, 24, and 48

  19. Adherence as measured by pill count at Weeks 4, 12, 24, and 48

    Adherence as measured by pill count at Weeks 4, 12, 24, and 48

    Time frame: Weeks 4, 12, 24, and 48

07

Study locations

1 site
  • The Crofoot Research Center, Inc.
    Houston, Texas 77098, United States
08

References and documents

Publications

  • Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18. PubMed 21767103 ↗
  • Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853-60. doi: 10.1056/NEJM199803263381301. PubMed 9516219 ↗
  • Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 dependent areas, 2016. HIV Surveillance Supplemental Report 2018;23(No. 4). http://www.cdc.gov/hiv/library/reports/ hiv-surveillance.html. Accessed [February 4, 2020]
  • Horberg MA, Hurley LB, Silverberg MJ, Klein DB, Quesenberry CP, Mugavero MJ. Missed office visits and risk of mortality among HIV-infected subjects in a large healthcare system in the United States. AIDS Patient Care STDS. 2013 Aug;27(8):442-9. doi: 10.1089/apc.2013.0073. Epub 2013 Jul 19. PubMed 23869466 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Apr 2024, 31 months.

Of 70 phase 4 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 47. This study's 31 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2020
First posted
May 14, 2020
StartActual
Sep 1, 2021
Primary completionActual
Apr 5, 2024
CompletionActual
Apr 5, 2024
Last update
Apr 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04388904
Lead sponsor
The Crofoot Research Center, Inc.
Responsible party
Sponsor
First posted
May 14, 2020
Start date
Sep 1, 2021
Primary completion
Apr 5, 2024
Completion
Apr 5, 2024
Last update
Apr 26, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Darunavir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion